Pulmonary sarcoidosis – European Clinical Trials Information Network

Study on the Effects of OATD-01 for Patients with Active Pulmonary Sarcoidosis

Mon, 04 May 2026 07:50:55 +0000

This clinical trial is focused on studying active pulmonary sarcoidosis, a condition where clusters of inflammatory cells, known as granulomas, form in the lungs. The study will test a new treatment called OATD-01, which is an oral medication designed to reduce this inflammation. The medication is taken in the form of film-coated tablets. Participants in the study will either receive OATD-01 or a placebo, which is a substance with no active medication.

The purpose of the study is to evaluate how well OATD-01 works in reducing lung inflammation over a 12-week period. Participants will be randomly assigned to receive either the medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. Throughout the study, participants will undergo various assessments, including imaging tests, to monitor changes in lung inflammation and overall health.

The study aims to gather information on the effectiveness and safety of OATD-01 for treating active pulmonary sarcoidosis. Participants will be closely monitored for any changes in their condition and any side effects they may experience. The study will help determine if OATD-01 can be a beneficial treatment option for people with this condition.

Study on Methotrexate and Prednisone for Treating Lung Sarcoidosis in Patients

Wed, 29 Apr 2026 14:57:36 +0000

This clinical trial is focused on studying the effectiveness of two medications, methotrexate and prednisone, as treatments for pulmonary sarcoidosis. Pulmonary sarcoidosis is a condition where small clusters of inflammatory cells, called granulomas, form in the lungs, which can affect breathing. The purpose of the study is to compare how well these two medications work as the first treatment option for this condition.

Participants in the study will be randomly assigned to receive either methotrexate or prednisone. Methotrexate is a medication that works by interfering with the growth of certain cells, while prednisone is a type of corticosteroid that helps reduce inflammation in the body. Both medications will be taken in tablet form by mouth. The study will last for a period of 24 weeks, during which the effects of the medications on lung function and overall health will be monitored.

Throughout the study, participants will have regular check-ups to assess their lung function and monitor any changes. The main focus will be on measuring the change in lung capacity, specifically the forced vital capacity, which is a measure of how much air a person can exhale after taking a deep breath. Additionally, other health markers, known as biomarkers, will be evaluated to provide further insights into the effectiveness and tolerability of the treatments.

Study on Efzofitimod for Treating Pulmonary Sarcoidosis in Patients

Wed, 29 Apr 2026 14:23:57 +0000

This clinical trial is focused on studying pulmonary sarcoidosis, a condition where clusters of inflammatory cells form in the lungs, affecting breathing and lung function. The study will evaluate the effectiveness and safety of a treatment called Efzofitimod, which is administered through an injection into the veins. This treatment is being compared to a placebo to determine its impact on the disease.

The purpose of the study is to assess how well Efzofitimod works in treating patients with pulmonary sarcoidosis. Participants in the study will receive either the treatment or a placebo over a period of time. The study will monitor changes in the participants’ condition, including any improvements in lung function and overall health. The treatment period is designed to last up to 48 weeks, during which participants will be closely observed by medical professionals.

Throughout the study, participants will undergo regular check-ups to track their progress and any side effects. The goal is to gather information on how Efzofitimod can help manage symptoms of pulmonary sarcoidosis and improve the quality of life for those affected by this condition. This research aims to provide valuable insights into new treatment options for patients with this lung disease.

Study of hydroxychloroquine with low-dose corticosteroids compared to medium-dose corticosteroids in patients with pulmonary sarcoidosis

Wed, 29 Apr 2026 14:22:36 +0000

This clinical trial focuses on treating patients with pulmonary sarcoidosis, a condition where inflammatory cells form small lumps called granulomas in the lungs. The study compares two treatment approaches: a combination of hydroxychloroquine with low-dose prednisone versus medium-dose prednisone alone. The purpose is to determine if the combination treatment works as effectively as the standard treatment with medium-dose prednisone in improving breathing function.

The study evaluates how well patients’ lung function improves over a period of 6 months. Participants receive either the combination of hydroxychloroquine and low-dose prednisone or medium-dose prednisone alone. The medications are taken by mouth daily. The treatment continues for 24 months while doctors monitor the patients’ progress.

Throughout the study, doctors track various aspects of the disease, including breathing capacity, quality of life, and any potential side effects from the medications. They also monitor how the disease affects different parts of the body and measure various indicators in the blood that show how active the disease is. This helps determine how well each treatment approach is working for the patients.